Have you been diagnosed with a cancer called Chronic Lymphocytic Leukemia (CLL)? . If so, you may be able to take part in a research study looking at the effectiveness of combination treatments of the drugs (sonrotoclax + Zanubrutinib) or (venetoclax + Obinutuzumab) for patients with Chronic Lymphocytic Leukemia (CLL) .

Have you been diagnosed with an advanced B-cell malignancy, such as Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL), non-GCB Diffuse Large B-Cell Lymphoma (DLBCL), Marginal Zone Lymphoma (MZL) or Waldenstrom Macroglobulinemia (WM) and have either had your disease relapse or not respond to treatment? If so, you may be eligible for a trial utilizing an investigational oral drug to treat your cancer.

This research study is looking to see 1) how well your breast cancer responds to preoperative treatment with endocrine therapy and 2) which endocrine therapy regimen is the most effective treatment for male breast cancer. The study includes a 3-week window phase containing endocrine therapy followed by a 4-month treatment phase where participants are treated with one of four endocrine therapy treatment combinations.

The purpose of this study to find out if enzalutamide, alone or combined with mifepristone, is effective in treating a specific type of breast cancer in comparison with standard chemotherapy with carboplatin, paclitaxel, capecitabine, or eribulin. The specific type of breast cancer include Triple-negative or ER/PgR-low and Androgen receptor positive breast cancer.

This study will investigate the safety and efficacy of a new drug DB-1303 against standard treatment procedure in patients with metastatic breast cancer. This study will also evaluate the efficacy of a diagnostic test that will be performed during the trial.

In this study, we want to see if a new medicine is safe and works well for adults with multiple myeloma cancer. These adults have already tried at least two other treatments, including specific types of medicines. This study can help us discover a new, safer treatment for this type of cancer.

Have you been diagnosed with breast cancer and completed your surgery? Has your doctor recommended hormonal therapy to help prevent your cancer from returning? You may be able to participate in a research study of a new drug called Camizestrant. Please reach out to the research team if you are interested and we will provide information regarding the next steps.

Do you have ovarian, peritoneal, or fallopian tube cancer that came back after receiving standard therapy? If so, you might be able to take part in a study that looks at a new treatment, iC9.CAR.B7-H3 cells, to test the safety of these cells and observe any side effects.

This study is for patients diagnosed with breast cancer that has spread to other parts of the body, which is called Metastatic Breast Cancer. This study will look at information from your tumor that may help choose treatments. Researchers will use this information to find out how different patients may respond to different treatments, leading to better treatments for future patients. You may not benefit personally, but your doctor may be given information which may help guide your treatments.

You are being asked to participate in this research study because you have been diagnosed with breast cancer and considered for immunotherapy. This study will investigate your response to immunotherapy.